Drugs /

mag-tn3/as15 vaccine

Back to Drugs List

Overview

NCI Definition [1]:
A vaccine containing synthetic multiple antigenic glycopeptide (MAG) composed of tri Tn glycotope (MAG-Tn3), which is comprised of a dendrimeric, nonimmunogenic lysine core linked to a tetravalent peptidic CD4+ T-cell epitope backbone and each attached to three Tn antigens (tri-Tn cluster), combined with the immunoadjuvant AS15, with potential antineoplastic activity. Upon administration of the MAG-Tn3/AS15 vaccine, MAG-Tn3 induces the production of tumor-specific anti-Tn glycosidic antibodies, which results in antibody-dependent cell cytotoxicity (ADCC) against Tn-expressing tumor cells. The Tn carbohydrate antigen, a tumor-associated antigen (TAA), is overexpressed in a number of tumor cell types. The tri-Tn clusters mimic carbohydrate structures found on tumor cells. The T-cell epitope stimulates effective T-cell responses. AS15, a potent adjuvant liposomal formulation that contains CpG 7909, monophosphoryl lipid (MPL), and QS-21, increases the immune response against the Tn antigens.

Clinical Trials

View Clinical Trials for mag-tn3/as15 vaccine

Mag-tn3/as15 vaccine has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating mag-tn3/as15 vaccine, 1 is phase 1 (1 open).

HER2 Deficient Expression and HER2 Negative are the most frequent biomarker inclusion criteria for mag-tn3/as15 vaccine clinical trials.

Breast carcinoma is the most common disease being investigated in mag-tn3/as15 vaccine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Mag-Tn3/as15 Vaccine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating mag-tn3/as15 vaccine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
mag-tn3 plus as15 vaccine, mag-tn3 plus as15 cancer vaccine, mag-tn3/as15, mag-tn3/as15 vaccine
NCIT ID [1]:
C120555

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.